Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Publication year range
1.
Ren Fail ; 23(3-4): 377-84, 2001.
Article in English | MEDLINE | ID: mdl-11499553

ABSTRACT

Urinary excretion of renal brush border enzymes may serve as an early marker of renal injury. However, the distinction between physiological and pathological levels remains controversial, since enzymuria is affected by physiological parameters. To clarify the influence of diuresis, we investigated the urinary excretion of alanine-aminopeptidase (AAP; EC 3.4.11.2) as function of diuretic state. 17 healthy volunteers of both sexes were subjected to protocols with sudden or prolonged water load preceded and followed by a thirst period. Urinary excretion of AAP was measured using an enzyme kinetic assay. As expected AAP excretion increased with urine flow, the increments diminished yielding an overall excretion pattern that resembled saturation kinetics. This function is described by a mathematical model. This model assumes, that AAP is released in proximal tubules at a constant rate and reabsorbed or inactivated in the distal tubule and collecting duct. Non-linear fits of the model equation to our data allowed two parameters, chi and mu, to be defined. Chi describes the rate of AAP release independent of urinary flow, and mu the ratio of distal tubular reabsorption or inactivation. If a substrate is not reabsorbed at all, mu approximates zero. Since mu fitted for AAP differed significantly from zero, this indicates reabsorption or inactivation of AAP in the distal nephron. Therefore, our study supports the theory of flow-dependent reabsorption or inactivation of AAP in the distal nephron.


Subject(s)
CD13 Antigens/urine , Diuresis/physiology , Adult , Female , Humans , Kidney Tubules, Distal/metabolism , Male , Microvilli/enzymology , Nonlinear Dynamics , Predictive Value of Tests , Reference Values
2.
Circulation ; 103(16): 2102-7, 2001 Apr 24.
Article in English | MEDLINE | ID: mdl-11319202

ABSTRACT

BACKGROUND: Oxidized LDL (oxLDL) inhibits endothelial cell (EC) migration. Stimulating ECs with vascular endothelial growth factor (VEGF) leads to the activation of Akt/protein kinase B, which in turn activates endothelial nitric oxide synthase (eNOS) by phosphorylation on serine 1177. VEGF-induced cell migration is dependent on the generation of nitric oxide (NO). Therefore, we investigated whether oxLDL affects EC migration by an inhibitory effect on the Akt/eNOS pathway. METHODS AND RESULTS: During an in vitro "scratched wound assay," oxLDL dose-dependently inhibited the VEGF-induced migration of human umbilical vein endothelial cells. Western blot analysis revealed that oxLDL dose- and time-dependently led to dephosphorylation and thus deactivation of Akt. Moreover, oxLDL inhibited the VEGF-induced generation of NO, as detected and quantified using a fluorescent NO indicator, 4,5-diaminofluorescein diacetate. Overexpression of a constitutively active Akt construct (Akt T308D/S473D) or a phosphomimetic eNOS construct (eNOS S1177D) almost completely reversed the inhibitory effect of oxLDL on VEGF-induced EC migration and NO generation. CONCLUSIONS: Our data indicate that oxLDL-induced dephosphorylation of Akt, followed by impaired eNOS activation, reduces the intracellular level of NO and thereby inhibits VEGF-induced EC migration.


Subject(s)
Cell Movement/drug effects , Endothelial Growth Factors/pharmacology , Endothelium, Vascular/drug effects , Lipoproteins, LDL/pharmacology , Lymphokines/pharmacology , Protein Serine-Threonine Kinases , Signal Transduction/drug effects , Amino Acid Substitution , Cell Line , Dose-Response Relationship, Drug , Endothelium, Vascular/cytology , Endothelium, Vascular/physiology , Enzyme Activation/drug effects , Humans , Nitric Oxide/metabolism , Nitric Oxide Synthase/genetics , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type III , Phosphorylation/drug effects , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-akt , Signal Transduction/physiology , Transfection , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
4.
FEBS Lett ; 472(1): 129-32, 2000 Apr 21.
Article in English | MEDLINE | ID: mdl-10781819

ABSTRACT

In mesangial cells angiotensin II (Ang II) has been shown to activate extracellular regulated kinases 1 and 2 (ERK1/2). Here, we studied the role of the epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR) in Ang II-induced ERK1/2 activation in human mesangial cells. Ang II induced activation of ERK1/2 via the AT(1) receptor, and this response was blocked by the PDGFR-selective tyrosine kinase inhibitor AG1295, but not by AG1478, an EGFR-selective tyrosine kinase inhibitor, indicating participation of the PDGFR, but not of the EGFR in Ang II-induced ERK1/2 activation. In agreement with this assumption, Ang II caused tyrosine phosphorylation of the PDGFR and the adapter protein Shc in an AG1295-sensitive fashion. In conclusion, our data show that Ang II-induced activation of mitogenic signalling cascade in human mesangial cells involves ligand-independent activation of the PDGFR, but not of the coexpressed EGFR.


Subject(s)
Angiotensin II/pharmacology , Glomerular Mesangium/metabolism , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinases/metabolism , Receptors, Platelet-Derived Growth Factor/metabolism , Blotting, Western , Cells, Cultured , ErbB Receptors/metabolism , Gene Expression Regulation , Glomerular Mesangium/cytology , Humans , Mitogen-Activated Protein Kinase 3 , Phosphorylation , Precipitin Tests , Receptor, Angiotensin, Type 1 , Receptor, Angiotensin, Type 2 , Receptors, Angiotensin/physiology
5.
Blood Press ; 9(5): 293-7, 2000.
Article in English | MEDLINE | ID: mdl-11193134

ABSTRACT

Hypertension has been recognized to be an important cause for the development of end-stage renal disease (ESRD). We assessed the quality of blood pressure control in 103 patients with essential hypertension and correlated renal function and age. Patients were stratified into three subgroups by their blood pressure level under current medication. Group 1 were hypertensive patients with normalized blood pressure (<140/90 mmHg, n = 25), group 2 patients with mild hypertension (140-159/90-99 mmHg, n = 43) and group 3 patients with moderate to severe hypertension (> 160/100 mmHg, n = 35). A negative correlation between age and creatinine clearance (Ccr) could be confirmed for patients of group 1 (correlation coefficient r1 = -0.56; p, < 0.01) and group 2 (r2 = -0.55; P2 < 0.001). Furthermore the regression coefficient (m) of decline in C(Cr) versus age was higher in group 2 patients (m2 = -1.83) than in group 1 (m1 = -1.30). In group 3 we found no correlation of renal function with age, indicating that age may not be the leading variable. Patients in group 1 were all within normal limits of age adjusted Ccr, but 12% in group 2 and 23% in group 3 had impaired C(Cr). Furthermore proteinuria was found to be 20% (group 1), 26% (group 2) and 31% (group 3). This analysis provides further evidence of the importance of blood pressure control in essential hypertension to preserve renal function.


Subject(s)
Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Hypertension/physiopathology , Kidney Failure, Chronic/prevention & control , Kidney/physiopathology , Adaptation, Physiological , Adult , Age Factors , Aged , Aged, 80 and over , Aging/physiology , Antihypertensive Agents/pharmacology , Blood Pressure/physiology , Creatinine/blood , Creatinine/urine , Female , Humans , Hypertension/drug therapy , Hypertension/metabolism , Kidney Failure, Chronic/etiology , Kidney Failure, Chronic/metabolism , Male , Middle Aged , Proteinuria/etiology
6.
Dtsch Med Wochenschr ; 124(41): 1201-3, 1999 Oct 15.
Article in German | MEDLINE | ID: mdl-10572517

ABSTRACT

HISTORY AND CLINICAL FINDINGS: A 21-year-old man was admitted twice within half-a-year because of fatigue and increasing dyspnoea. Both times the chest x-ray showed extensive pulmonary infiltrates. Clinical remission occurred within a few days of starting antibiotic treatment. INVESTIGATIONS: During the second admission an increased titre for antibodies against glomerular basement membrane was discovered (2560 U/ml); renal functions were normal, but there was haematuria. Renal biopsy revealed linear deposits of IgG along the glomerular basement membrane. DIAGNOSIS, TREATMENT AND COURSE: The pattern of findings indicated Goodpasture's syndrome. Immunosuppressive treatment and plasma separation did not have to be performed because spontaneous remission occurred within a few days. CONCLUSION: This case demonstrates that spontaneous remission may occur in Goodpasture's syndrome.


Subject(s)
Anti-Glomerular Basement Membrane Disease , Adult , Anti-Glomerular Basement Membrane Disease/diagnosis , Anti-Glomerular Basement Membrane Disease/pathology , Biopsy , Humans , Kidney/pathology , Male , Radiography, Thoracic , Remission, Spontaneous
7.
Kidney Int ; 55(4): 1359-66, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10201000

ABSTRACT

BACKGROUND: Renal disease is commonly associated with hyperlipidemia and correlates with glomerular accumulation of atherogenic lipoproteins, for example, lipoprotein(a) [Lp(a)], and mesangial hypercellularity. Specific binding of Lp(a) to mesangial cells and induction of c-myc and c-fos expression has been demonstrated. Therefore, in this study, we investigated a possible growth stimulatory effect and mode of action of Lp(a) in human mesangial cells. METHODS: Lp(a) was purified from the regenerate fluid of a dextran sulfate column-based low-density lipoprotein apheresis system. Human mesangial cells were isolated by a sequential sieving technique from patients undergoing tumor nephrectomy. DNA synthesis was measured by [3H]-thymidine incorporation. The intracellular calcium concentration ([Ca2+]i) was determined by Fura 2-fluorescence, and inositol 1,4,5-trisphosphate (1,4,5-IP3) concentration was measured by a radioreceptor assay. RESULTS: The data show that Lp(a) bound to the cells with a Kd of 17.0 micrograms/ml and increased DNA synthesis and cell proliferation. Lp(a) caused a rapid increase in 1,4,5-IP3 and [Ca2+]i via a pertussis toxin-sensitive mechanism. The phospholipase C (PLC) inhibitor U73122 abolished Lp(a)-induced cell proliferation. In contrast, vasopressin-induced increase in 1,4,5-IP3 and [Ca2+]i was pertussis toxin insensitive. CONCLUSION: This study revealed that Lp(a) stimulates growth of human mesangial cells. Lp(a)-induced signaling involves binding to a receptor and stimulation of PLC via Gi proteins. Stimulation of PLC appears to be essential for the growth stimulatory effect of Lp(a). Whether these effects of Lp(a) contribute to the pathophysiology of renal disease needs to be determined.


Subject(s)
GTP-Binding Proteins/metabolism , Glomerular Mesangium/drug effects , Lipoprotein(a)/pharmacology , Type C Phospholipases/metabolism , Blood Proteins/pharmacology , Calcium/metabolism , Cell Division/drug effects , DNA/biosynthesis , Dose-Response Relationship, Drug , Egtazic Acid/pharmacology , Enzyme Activation/drug effects , Estrenes/pharmacology , Glomerular Mesangium/cytology , Glomerular Mesangium/metabolism , Humans , Inositol 1,4,5-Trisphosphate/metabolism , Intracellular Fluid/drug effects , Intracellular Fluid/metabolism , Lipoprotein(a)/metabolism , Pertussis Toxin , Phosphodiesterase Inhibitors/pharmacology , Pyrrolidinones/pharmacology , Type C Phospholipases/antagonists & inhibitors , Vasopressins/pharmacology , Virulence Factors, Bordetella/pharmacology
8.
Am J Hypertens ; 11(2): 174-83, 1998 Feb.
Article in English | MEDLINE | ID: mdl-9524045

ABSTRACT

The renin-angiotensin system (RAS) is involved in the pathogenesis of essential hypertension. In the present study we examined the genotype frequencies of the insertion/deletion polymorphisms of the ACE gene and the M235T polymorphism of the Angiotensinogen (Agt) gene in patients with essential hypertension in comparison with normotensive subjects. In hypertensive patients functional effects of blood pressure response to ACE inhibition were investigated. A total of 121 patients with essential hypertension (group 1) and 125 normotensive control subjects (group 2) were included in this study. All patients were genotyped by polymerase chain reactions (PCR) for the insertion/deletion (I/D) polymorphism of the ACE gene and the M235T polymorphism of the Agt gene. To analyze possible functional impacts on blood pressure regulation 50 mg of captopril was administered to hypertensive patients. No significant association of essential hypertension with polymorphisms of the Agt and ACE gene was found. The ACE serum levels in patients with the DD-genotype of the ACE I/D polymorphism were higher than in patients with the II-genotype (P < .01). In patients with the ID-genotype the ACE serum levels were in-between. A captopril test was performed in hypertensive patients. The patients were further divided into subgroups according to the diastolic and systolic blood pressure response. Group 1a consisted of patients with a diastolic blood pressure drop of > 5 mm Hg and group 1b with < or =5 mm Hg. Group 1c consisted of patients with a systolic blood pressure drop of > 10 mm Hg and group 1d with < or =10 mm Hg. Twice as many patients with the DD genotype of the ACE gene were found in group 1a compared to group 1b (chi(2) = 5.673; P = .017). No association of systolic blood pressure change to the investigated polymorphisms was found. Our results do not support the hypothesis that the investigated polymorphisms contribute to essential hypertension. Furthermore, no major impact of these polymorphisms on blood pressure response to captopril were detected. We conclude that the investigated genotypes have no influence on blood pressure level and homeostasis.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Angiotensinogen/genetics , Captopril/therapeutic use , Hypertension/drug therapy , Peptidyl-Dipeptidase A/genetics , Polymorphism, Genetic , Adult , Aged , Female , Genotype , Humans , Hypertension/genetics , Male , Middle Aged , Peptidyl-Dipeptidase A/blood
9.
FEBS Lett ; 441(2): 205-8, 1998 Dec 18.
Article in English | MEDLINE | ID: mdl-9883885

ABSTRACT

Evidence suggests an important role of elevated serum lipoproteins in the progression of renal glomerulosclerosis. We report here that lipoprotein (a) (Lp(a)) increased phosphorylation and activity of mitogen activated protein kinase (MAPK) in human mesangial cells. When protein kinase C (PKC) was depleted by long-term incubation with the phorbol 12-O-myristate 13-acetate the effect of Lp(a) on MAPK activation was completely inhibited. Forskolin, a stimulator of the adenylyl cyclase, and dibutyryl-cAMP reduced the effect of Lp(a) on MAPK phosphorylation and activation. We conclude that Lp(a) stimulates the MAPK cascade via activation of PKC and that activation of protein kinase A counteracts Lp(a) induced MAPK activation in human mesangial cells.


Subject(s)
Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Glomerular Mesangium/drug effects , Lipoprotein(a)/pharmacology , Cells, Cultured , Cyclic AMP/pharmacology , Enzyme Activation , Glomerular Mesangium/cytology , Glomerular Mesangium/enzymology , Humans , Phosphorylation , Protein Kinase C/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...